The Medical Advisor

Prostate cancer remains a significant global health challenge, impacting millions of men each year. In 2022, more than 1.4 million new cases were reported worldwide, ( 1 ) with projections estimating 313,780 new diagnoses in the United States by 2025 ( 2 ). In the UK, prostate cancer accounts for 28% of all new cancer cases in males, with approximately 1 in 8 men being diagnosed over their lifetime ( 3 ). As  one Sermo member  specializing in oncology put it: “Prostate cancer is the #2 cancer killer in men. We need to do something. 4 ” This highlights the urgent need for effective prevention, treatment and awareness initiatives.In this article, we delve into the treatments currently used, as mentioned by doctors inside Sermo’s free physician-only community, and explore the  latest advancements  shaping the future of prostate cancer care. What current treatments do physicians on Sermo use? Physicians on Sermo constantly refine their approaches to provide personalized,...

An evidence‑aware guide to off‑label cancer therapies, integrative oncology, precision oncology and emerging research — without hype or false promises. This page serves as the central hub for OneDayMD’s coverage of repurposed drugs and precision oncology in cancer care, integrating conventional oncology standards with systems biology, real‑world data, and ethical analysi s. What This Hub Covers (Quick Overview) This hub explains: What repurposed drugs are — and what they are not. Which drugs show credible anti‑cancer signals vs speculation. How repurposed therapies may (or may not) integrate with standard oncology. The evidence hierarchy used across OneDayMD. Safety, ethics, and regulatory realities. It is designed for patients, clinicians, and researchers seeking clarity rather than promotion . Diverse cancer hallmarks targeted by repurposed non-oncology drugs. This figure was created with Biorender.com. Source:  Nature 2024 Executive Summary Repurposed drugs in cancer care ref...

Abstract Background: Lung cancer, particularly advanced or metastatic non–small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), remains a leading cause of cancer mortality worldwide. Conventional therapies such as targeted agents, immunotherapy, and chemotherapy offer survival benefits but often yield limited results in treatment-resistant or late-stage disease. Repurposing widely available antiparasitic drugs — fenbendazole , ivermectin , and mebendazole — has garnered attention in integrative oncology communities due to reported anticancer effects in preclinical studies and emerging anecdotal clinical observations. Objective: To summarize a compilation of real-world case reports describing the use of fenbendazole, ivermectin, and mebendazole in lung cancer patients, highlighting reported clinical outcomes and therapeutic contexts. Methods: This review synthesizes case narratives and outcome descriptions publicly shared through online platforms, including clinicians...